The FDA has confirmed that the shortage of semaglutide injection products has been resolved.

This shortage began in March 2022 for Wegovy and in August 2022 for Ozempic. The FDA will continue to monitor the supply and demand for these products.

For more details, see the FDA statement on the resolution of the shortage: https://ow.ly/Tuao50V62Z8 and the Declaratory Order: https://ow.ly/fGvb50V62Z6.

*    *    *